Leverage, Debt Maturities & Coverage
Cardinal Health maintains a moderate leverage profile and a solid balance sheet, especially given its enormous revenue scale. As of June 30, 2023, the company had $4.7 billion in total long-term obligations (including the current portion of debt and short-term borrowings) (content.edgar-online.com). This is a manageable debt load for a business generating over $2 billion in annual operating profit and cash flow. In fact, Cardinal’s debt covenant requires a net leverage ratio no higher than 3.75× EBITDA, a threshold the company “was in compliance with” as of mid-2023 (content.edgar-online.com). This implies Cardinal’s actual debt/EBITDA is comfortably below 3.75× (by our estimates likely in the 2×–3× range). Moreover, interest coverage is very strong – interest expense has been running under $100 million per year net of interest income, while operating earnings are in the $2 billion+ range (content.edgar-online.com). In FY2023, net interest expense fell to just $93 million (down from $149 million in FY2022) as higher interest income on cash balances offset interest costs (content.edgar-online.com). This low interest burden – roughly 4% of operating profit – means Cardinal can comfortably cover its debt service many times over, even if interest rates rise.
Another reassuring aspect is debt maturity spacing. Cardinal’s upcoming debt maturities are staggered over several years, which reduces refinancing risk. According to the latest filings, only about $764 million of the debt comes due in fiscal 2024, with roughly $917 million due in FY2025-2026 and $1.3 billion in FY2027-2028 (content.edgar-online.com). The largest chunk (approximately $4.6 billion) of debt is not due until after 2028 (content.edgar-online.com). This long-dated maturity profile gives the company flexibility to repay or refinance obligations on reasonable terms. Indeed, Cardinal has been proactively paying down debt; in FY2023 it repaid a $550 million note that matured (and in FY2022 it redeemed about $854 million of notes early) using available cash (content.edgar-online.com). With a BBB/Baa2 credit rating (investment-grade) and strong banking relationships, Cardinal should have continued access to liquidity for any refinancing or strategic needs. Overall, leverage is well under control: the company’s strong cash flows and $4–5 billion of debt result in a healthy balance sheet that poses little risk to the bull thesis. In fact, management touts the “strong balance sheet [and] robust cash flow generation” as enablers of its growth and shareholder return plans (newsroom.cardinalhealth.com).
Valuation and Peer Comparisons
Despite its recent rally, Cardinal Health’s valuation still appears undemanding relative to both peers and its improving fundamentals. The stock trades at about 13×–15× forward earnings, based on FY2024 non-GAAP EPS guidance ($6.50–$6.75) (newsroom.cardinalhealth.com) and the current market price. This is a modest multiple given the company’s projected mid-teens earnings growth and defensive industry. On a cash flow basis, the stock’s free cash flow yield is around 10% (using normalized FCF of ~$2 billion on a ~$20 billion market cap in mid-2023), which is quite attractive for a stable healthcare business. Furthermore, EV/EBITDA multiples indicate a value gap: Cardinal’s enterprise value has been around 8× EBITDA, which lags peers like McKesson or AmerisourceBergen trading ~10–11× EBITDA (www.cnbc.com). Notably, Cardinal’s pharmaceutical distribution segment is growing faster than those peers (e.g. +14% revenue growth at the time of the Elliott stake (www.cnbc.com)), yet the market has historically assigned Cardinal a lower multiple due to the drag from its medical division. This conglomerate discount has created an opportunity.
A sum-of-the-parts view underscores the undervaluation. Cardinal’s pharmaceutical segment earns roughly ~$2 billion in annual EBITDA (www.cnbc.com). If one applies a typical 10×–11× EBITDA multiple (in line with peers and industry transactions) to that segment alone, it would be worth on the order of $20–22 billion – roughly equal to Cardinal’s entire current enterprise value (www.cnbc.com). In other words, at recent prices the market was attributing essentially zero (or even negative) value to the Medical segment, despite that division generating ~$16 billion of annual revenue (www.cnbc.com). This disconnect suggests significant upside if the Medical segment’s performance improves (or if the company were to separate or divest it – see Open Questions below). Even after the stock’s climb from its 2022 lows (~$50–$70 range) to around $90–$100 by late 2023, many analysts still see Cardinal as undervalued relative to its intrinsic worth. The forward P/E remains below the broader market’s (~18×) and below some healthcare peers, despite Cardinal’s above-average yield and earnings growth outlook. Additionally, the robust share buybacks are boosting EPS and effectively put a floor under the valuation by signaling that management views shares as cheap. Given the ongoing earnings rebound and double-digit growth forecast, a case can be made that Cardinal’s multiple should re-rate higher, closer to peers – which would further drive share price appreciation. In summary, the valuation setup provides a margin of safety for bulls: the stock is priced as if Cardinal’s issues will persist, but if those issues are resolved, multiple expansion could augment returns on top of earnings growth.
Key Risks and Red Flags
No investment is without risks, and Cardinal Health does face several risk factors and potential red flags that investors should monitor. First and foremost is the Medical segment’s historic underperformance. Cardinal made a series of acquisitions in its Medical business (e.g. the Cordis medical devices unit) that proved problematic, leading to operating losses and heavy write-downs. In FY2022-2023, the company recorded over $1.5 billion in goodwill impairments related to the Medical segment (including a $1.2 billion non-cash charge in FY2023) (newsroom.cardinalhealth.com). These impairments underscore that Cardinal overpaid or failed to integrate some medical assets – essentially destroying shareholder value. While the Medical unit has now begun to turn around (it produced a profit of $82 million in Q4 FY2023, versus losses earlier) (newsroom.cardinalhealth.com), it remains a work-in-progress. Execution risk is significant: if the Medical Improvement Plan falls short of its FY2026 goal (>$650 million segment profit (newsroom.cardinalhealth.com)), Cardinal’s overall earnings could lag expectations. Any stumble in execution, cost overruns, or inability to recapture lost margins in the Medical segment would be a bearish signal.
Another major risk involves margin pressures and cost inflation. Cardinal’s manufacturing and supply operations rely on raw materials like cotton, latex, resin, and pulp for products such as gloves and surgical apparel. The company has warned that input prices for these materials “fluctuate significantly” and that it has “recently experienced [cost] increases which have adversely impacted Medical segment profits”, with these challenges expected to continue (www.nasdaq.com). Higher oil and transport costs likewise raise distribution expenses (www.nasdaq.com). This means Cardinal’s margins – especially in the Medical division – can be squeezed if inflation in materials, labor, or freight outpaces its ability to pass on costs. The generic drug pricing environment is another factor: in pharmaceutical distribution, periods of generic drug deflation have historically hurt wholesalers’ profitability. Cardinal must manage these industry cycles and maintain efficient operations to protect its thin gross margins.
Legal and regulatory risks are also pertinent. Cardinal Health, along with its peers, was a defendant in nationwide opioid litigation and has entered into settlement agreements that will cost the company approximately $5.8 billion over an 18-year period (content.edgar-online.com). While Cardinal has reserved for this and begun making payments, any deviation from settlement assumptions or new litigation (e.g. related to the opioid crisis or other pharmaceutical practices) could create financial strain. More broadly, as a healthcare distributor, Cardinal is subject to extensive regulation (DEA, FDA, etc.) and could face fines or restrictions if it fails to comply with controlled substance handling or other laws. Regulatory changes in drug pricing, reimbursement, or pharmacy procurement could also impact Cardinal’s business model. For example, proposals to reduce drug supply chain intermediaries or new pharmacy benefit structures (perhaps through Amazon or other disruptive entrants) are a low-probability but notable longer-term threat to the traditional distribution oligopoly.
Additionally, customer concentration and competitive dynamics present a risk. A few large customers (such as CVS Health and hospital buying groups) account for a significant portion of Cardinal’s Pharmaceutical segment revenue. The company fortunately extended its key distribution contract with CVS through 2027 (www.nasdaq.com), providing near-term stability, but losing a major customer in the future or seeing a big client consolidate (e.g. through M&A) could sharply reduce volume. Cardinal’s position as the #3 player means it must continually defend its share and pricing against very strong competitors (McKesson, Amerisource). Razor-thin margins in drug distribution leave little room for error – operational hiccups or pricing concessions can have outsized effects on profit.
Finally, investors should note the leadership changes and governance concerns that led to the current turnaround. In 2022, the long-time CEO was abruptly replaced by the CFO, Jason Hollar, who had limited healthcare industry experience (www.cnbc.com). This unplanned succession (prior to Elliott’s involvement) was seen as a red flag in terms of board oversight (www.cnbc.com). While the board has since been refreshed – adding four new directors aligned with the activist’s input (newsroom.cardinalhealth.com) (newsroom.cardinalhealth.com) – and Hollar has thus far executed well, management’s ability to deliver on the multi-year improvement strategy remains a risk to monitor. Any return to inconsistent results (recall that Cardinal missed earnings guidance 6 quarters in a row before the shake-up (www.cnbc.com)) would undermine confidence in the bull thesis. In short, Cardinal Health must prove that its recent positive momentum is sustainable. Key risks like Medical segment turnaround, cost inflation, and industry/regulatory challenges are meaningful headwinds. However, the company’s actions – cost-saving initiatives, strategic refocus, and conservative financial management – are aimed at mitigating these risks. Investors should keep an eye on these red flags, but if Cardinal continues to navigate them successfully, the bull case remains intact.
Open Questions and Bull Case Outlook
Looking ahead, there are a few open questions that could influence Cardinal Health’s equity story and the realization of the bull case. One major question is strategic optionality: Will Cardinal eventually restructure or separate its two disparate segments? The Pharmaceutical and Medical businesses have few synergies and some analysts have argued that breaking them up could unlock shareholder value (www.cnbc.com). For instance, Cardinal’s Nuclear & Precision Health Solutions unit (a niche radiopharmacy business within the pharma segment) is a market leader in its space but not core to distribution – it could potentially be spun off or sold to realize value (www.cnbc.com). Likewise, within the Medical segment, Cardinal operates an “At-Home Solutions” business (medical supplies for home care) that has grown nicely and could fetch a good price if divested (www.cnbc.com). Monetizing one or more of these non-core assets could generate cash to reinvest in core operations or return to shareholders. More radically, if the Medical segment’s turnaround falters, the company could consider spinning off the entire Medical division once it’s stabilized. As discussed above, the sum-of-parts suggests that Cardinal’s stock is penalized by the underperforming segment (www.cnbc.com). A successful spinoff or sale might remove that overhang – effectively crystallizing the value of the higher-multiple Pharmaceutical segment and allowing the Medical segment to be valued on its own merits. So far, management’s stance (influenced by the new Business Review Committee) has been to fix, not split, the company – focusing on executing the improvement plan rather than pursuing a breakup (newsroom.cardinalhealth.com). The open question remains whether further structural changes will be pursued down the road. This will depend on how the turnaround progresses and whether the market continues to undervalue the combined entity. Bulls speculate that even the prospect of such moves provides a “backstop” of value in the stock.
Another open question revolves around growth opportunities and capital allocation. Cardinal has emphasized expanding in Specialty pharmaceuticals (e.g. oncology and biologic drug distribution) as a key growth driver (newsroom.cardinalhealth.com). The company’s ability to capture share in specialty distribution – which tends to have higher margins and growth rates – will be important to hitting its long-term targets. How much will Cardinal invest in new capabilities or partnerships in this area? Will it pursue acquisitions to bolster its specialty or Medical product offerings? The capital allocation framework unveiled at Investor Day balances such growth investments with shareholder returns (newsroom.cardinalhealth.com). But if attractive acquisition opportunities arise (or if the Medical turnaround requires more resources), management may need to adjust priorities. So far, Cardinal has demonstrated discipline – returning cash to shareholders while funding internal initiatives – yet investors will be watching if future capital deployment stays balanced. Additionally, on the dividend front, an open question is whether the company will eventually accelerate dividend growth once earnings growth picks up. With payout ratios so low, there is room to raise the dividend faster (or perhaps issue special dividends), but so far the preference has been buybacks and modest dividend hikes. Income-focused investors will be looking for any signal of a policy shift here.
Finally, the sustainability of the turnaround momentum is an overarching question. FY2023 marked an “inflection point” according to CEO Jason Hollar (newsroom.cardinalhealth.com), with both segments improving and guidance on the rise. Cardinal now expects mid-teens EPS growth in FY2024 and has set an aggressive multi-year outlook (newsroom.cardinalhealth.com). The bull case assumes the company can deliver on these targets, proving that the past struggles are behind it. If Cardinal meets or exceeds its ~12–14% EPS CAGR goal, the stock should respond accordingly – especially given the low starting valuation. However, if growth falls short or new issues emerge, the bull thesis could be delayed or derailed. For now, the evidence is encouraging: Cardinal’s Pharmaceutical segment is posting solid profit growth, the Medical segment is gradually recovering margins, and management’s actions (cost cuts, portfolio review, and capital returns) are driving tangible results. The board’s cooperation with Elliott Management has thus far been constructive, and shareholder value creation is a clear priority (www.prnewswire.com) (newsroom.cardinalhealth.com). In summary, Cardinal Health’s bull case rests on continued execution of its turnaround and growth plans – with a tailwind from share buybacks and a valuation that still leaves room for upside. The coming quarters will be crucial to watch. If Cardinal keeps hitting its targets and addressing its challenges, the stock’s re-rating could have further to run. Investors are effectively asking: Can this Aristocrat distributor sustain its renaissance and fully “unlock” the value that skeptics have been missing? If the answer is yes, then CAH’s bull case – underpinned by improving fundamentals, shareholder-friendly policies, and latent sum-of-parts value – could very well play out favorably from here. (newsroom.cardinalhealth.com) (www.cnbc.com)
